FDA regulatory & patent intelligence
Loss-of-exclusivity intelligence, drawn from the public record.
LOERadar consolidates FDA drug patent listings, exclusivity periods, Hatch-Waxman litigation, and LOE timelines from seventeen public sources into one research interface — so practitioners stop cross-referencing the Orange Book, PTAB, PACER, and SEC filings by hand.
Apixaban
Eliquis®Bristol-Myers Squibb · NDA 202155 · Oral tablet
Coverage reflects the public record. Calculated dates and loss-of-exclusivity estimates are algorithmically derived and should be independently verified.
The single pane of glass
Everything one drug touches, on one page.
The data professionals already cross-reference by hand — the Orange Book, Drugs@FDA, PTAB, PACER, ClinicalTrials.gov, Medicare pricing, and SEC filings — collected, structured, and linked together.
Drug-level reference pages
Each FDA application has one consolidated page: listed patents classified by type, exclusivity periods, approval history, Paragraph IV activity, PTAB proceedings, litigation, SEC-reported revenue, Medicare spending, clinical trials, and related news — all from public records.
Patent & exclusivity monitoring
The platform tracks patent listings and exclusivity codes across the full Orange Book, identifies upcoming expirations, and flags changes — new listings, delistings, or code modifications — on a daily basis.
Litigation & PTAB tracking
Hatch-Waxman cases (NOS 835) from PACER, IPR/PGR proceedings from the USPTO, and ITC Section 337 investigations are indexed and associated with the drug applications and Orange Book patents they touch.
Regulatory filing activity
Paragraph IV certifications, citizen petitions under section 505(q), suitability petitions under 21 CFR 314.93, FDA approval letters, and Federal Register notices are collected and organized by drug and applicant.
Change detection & alerts
When data changes across any monitored source — a patent delisted, a new PTAB proceeding filed, a generic application approved — the platform identifies the change and can deliver a notification summarizing what moved.
Searchable browse views
Structured views filter and sort across patent cliffs, NCE expirations, biologics and biosimilars, therapeutic areas, company portfolios, drug pricing, and clinical trials. Every view supports CSV export.
Public sources only
Built entirely on the public record.
Every record is drawn from publicly available sources, collected and cross-referenced on a recurring schedule.
FDA Orange Book
Patent listings, exclusivities, products
Drugs@FDA
Approvals, submissions, labels, marketing status
USPTO PTAB
IPR, PGR, CBM proceedings and patent families
Patent Reexaminations
USPTO ex parte and inter partes proceedings
Regulations.gov
FDA citizen petitions (505(q), suitability)
News & Federal Register
20+ pharma RSS feeds, Federal Register, Google News
SEC EDGAR
10-K/10-Q intelligence, 8-K events, XBRL revenue
ClinicalTrials.gov
Active and recently updated trials by ingredient
NADAC Pricing
Pharmacy acquisition costs per NDC
USITC IDS
ITC Section 337 investigations, patents, orders
FDA Paragraph IV
Paragraph IV certification listings
Purple Book
Licensed biologics, biosimilars, interchangeables
VA FSS Pricing
Government-negotiated drug prices
Medicare Part D
Drug spending, claims, beneficiaries
Medicare Part B
Physician-administered drug spending and ASP
PACER
Hatch-Waxman ANDA litigation (NOS 835)
openFDA API
Drug enrichment, labels, NDC crosswalk
Attorney Advertising
LOERadar is an informational research and data-organization tool. It is not a law firm and does not provide legal advice or engage in the practice of law, and access to or use of the platform does not create an attorney-client relationship with Polsinelli PC or any other person. Polsinelli’s sponsorship of this tool does not constitute legal advice or a solicitation, and nothing here should be relied upon as a substitute for independent legal analysis, regulatory advice, or professional judgment. All data is aggregated from publicly available sources; LOERadar is not affiliated with, endorsed by, or sponsored by the FDA, USPTO, or any government agency. Calculated dates, loss-of-exclusivity estimates, and automated associations are derived algorithmically from public records, may contain errors or omissions, and should be independently verified before being relied upon for any matter-specific purpose.
See our Terms of Service and Privacy Policy.